Boule Diagnostics
- RevenueKR463.3 MFY, 2021
- Market CapitalizationKR495.1 M2022-08-02
OverviewSuggest Edit
Boule Diagnostics, a diagnostics company, develops, manufactures, and distributes instruments and consumable products for hematology diagnostics for the public healthcare providers. It provides hematology analyzers, reagents, controls, and calibrators, as well as cleaning kits and plastic micro capillaries under the Swelab, Medonic, and Quintus brands; and veterinary hematology system under the Exigo brand. The Company serves hospitals, clinics, laboratories, and companies in blood diagnostics.
| Type | Public | |
| Founded | 1956 | |
| HQ | Spånga, SE | Map |
| Website | boule.com |
Key People/Management at Boule Diagnostics
Peter von Ehrenheim
Karin Dahllöf
Christina Rubenhag
Boule Diagnostics Office Locations
Boule Diagnostics Financials and Metrics
Boule Diagnostics Revenue
| SEK | |
|---|---|
Revenue (Q2, 2022) | 140.8m |
Gross profit (Q2, 2022) | 66.6m |
Gross profit margin (Q2, 2022), % | 47.3% |
Net income (Q2, 2022) | 2.9m |
EBITDA (Q2, 2022) | 5.0m |
EBIT (Q2, 2022) | 5.0m |
Market capitalization (2-Aug-2022) | 495.1m |
Closing stock price (2-Aug-2022) | 26.2 |
Cash (30-Jun-2022) | 40.5m |
EV | 671.4m |
| SEK | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Revenue | 424.4m | 498.9m | 400.5m | 463.3m |
Cost of goods sold | (226.2m) | (251.5m) | (201.0m) | (241.2m) |
Gross profit | 199.4m | 249.2m | 211.8m | 222.8m |
Gross profit Margin, % | 47% | 50% | 53% | 48% |
| SEK | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 | Q2, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 118.6m | 119.7m | 131.2m | 118.4m | 90.6m | 98.8m | 100.6m | 110.7m | 111.8m | 132.5m | 140.8m |
Cost of goods sold | (64.5m) | (67.7m) | (68.9m) | (63.2m) | (53.6m) | (53.0m) | (51.7m) | (64.6m) | (61.8m) | (71.1m) | (87.6m) |
Gross profit | 58.0m | 54.4m | 66.4m | 62.7m | 41.3m | 60.9m | 51.7m | 47.7m | 51.1m | 64.5m | 66.6m |
Gross profit Margin, % | 49% | 45% | 51% | 53% | 46% | 62% | 51% | 43% | 46% | 49% | 47% |
| SEK | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Cash | 30.3m | 21.6m | 33.0m | 38.2m |
Accounts Receivable | 110.9m | 127.4m | 93.6m | 127.9m |
Prepaid Expenses | 20.8m | 19.1m | 11.2m | 14.0m |
Inventories | 58.0m | 57.6m | 54.5m | 59.0m |
| SEK | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 | Q2, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 16.8m | 17.0m | 19.2m | 26.6m | 35.7m | 39.6m | 31.5m | 27.7m | 35.7m | 36.2m | 40.5m |
Accounts Receivable | 124.0m | 116.0m | 129.1m | 137.4m | 115.9m | 119.4m | 106.7m | 111.0m | 109.6m | 137.5m | 139.0m |
Prepaid Expenses | 20.8m | 25.9m | 29.6m | 20.1m | 11.8m | 17.3m | 23.3m | 22.1m | 20.7m | 9.6m | 9.0m |
Inventories | 62.1m | 58.6m | 61.4m | 65.2m | 69.6m | 55.7m | 51.1m | 58.9m | 57.9m | 69.4m | 67.2m |
| SEK | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Net Income | 54.8m | 70.0m | (5.9m) | 36.0m |
Depreciation and Amortization | 8.4m | 21.4m | 21.6m | 21.5m |
Inventories | (5.7m) | 1.3m | (1.4m) | (3.0m) |
| SEK | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 | Q2, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 16.7m | 22.6m | 71.6m | 15.2m | 12.2m | 50.9m | 6.8m | 9.1m | 28.9m | 10.3m | 15.3m |
Inventories | (3.4m) | 100.0k | (5.0m) | (6.1m) | (11.9m) | (4.7m) | 4.6m | (3.5m) | 2.0m | (11.2m) | (3.7m) |
| SEK | FY, 2018 |
|---|---|
Debt/Equity | 0.3 x |
Debt/Assets | 0.2 x |
Financial Leverage | 1.7 x |
Boule Diagnostics Revenue Breakdown
Boule Diagnostics revenue breakdown by business segment: 16.0% from INSTRUMENTS, 20.9% from CONSUMABLES OWN INSTRUMENTS, 9.1% from CONSUMABLES OEM AND CDS-BRAND, 50.0% from HEALTH CARE DIVERSIFIED and 3.9% from Other
Boule Diagnostics revenue breakdown by geographic segment: 100.0% from SWEDEN
Boule Diagnostics Cybersecurity Score
Boule Diagnostics Environment, Social & Governance (ESG) Ratings
Boule Diagnostics Online and Social Media Presence
Boule Diagnostics's Trends
Boule Diagnostics Blogs
Interpretation of a histogram – Veterinary focus
Boule Diagnostics – Invitation to presentation of the interim report Q2 2022
Hematology needs – a clinicians perspective
Bulletin from Annual General Meeting in Boule Diagnostics AB on May 5, 2022
Boule Diagnostics Frequently Asked Questions
When was Boule Diagnostics founded?
Boule Diagnostics was founded in 1956.
Who are Boule Diagnostics key executives?
Boule Diagnostics's key executives are Peter von Ehrenheim, Karin Dahllöf and Christina Rubenhag.
How many employees does Boule Diagnostics have?
Boule Diagnostics has 218 employees.
What is Boule Diagnostics revenue?
Latest Boule Diagnostics annual revenue is kr463.3 m.
What is Boule Diagnostics revenue per employee?
Latest Boule Diagnostics revenue per employee is kr2.1 m.
Who are Boule Diagnostics competitors?
Competitors of Boule Diagnostics include Owlstone Medical, MasSpec Pen and Bactiguard.
Where is Boule Diagnostics headquarters?
Boule Diagnostics headquarters is located at 4 Domnarvsgatan, Spånga.
Where are Boule Diagnostics offices?
Boule Diagnostics has offices in Spånga, Plantation and Moskva.
How many offices does Boule Diagnostics have?
Boule Diagnostics has 3 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies